Development and verification of a combined immune- and cancer-associated fibroblast related prognostic signature for colon adenocarcinoma
Jingsun Wei,Xiaoxu Ge,Yucheng Qian,Kai Jiang,Xin Chen,Wei Lu,Hang Yang,Dongliang Fu,Yimin Fang,Xinyi Zhou,Qian Xiao,Yang Tang,Kefeng Ding
DOI: https://doi.org/10.3389/fimmu.2024.1291938
IF: 7.3
2024-01-19
Frontiers in Immunology
Abstract:Introduction: To better understand the role of immune escape and cancer-associated fibroblasts (CAFs) in colon adenocarcinoma (COAD), an integrative analysis of the tumor microenvironment was performed using a set of 12 immune- and CAF-related genes (ICRGs). Methods: Univariate and least absolute shrinkage and selection operator (LASSO) Cox regression analyses were used to establish a prognostic signature based on the expression of these 12 genes ( S1PR5 , AEN , IL20RB , FGF9 , OSBPL1A , HSF4 , PCAT6 , FABP4 , KIF15 , ZNF792 , CD1B and GLP2R ). This signature was validated in both internal and external cohorts and was found to have a higher C-index than previous COAD signatures, confirming its robustness and reliability. To make use of this signature in clinical settings, a nomogram incorporating ICRG signatures and key clinical parameters, such as age and T stage, was developed. Finally, the role of S1PR5 in the immune response of COAD was validated through in vitro cytotoxicity experiments. Results: The developed nomogram exhibited slightly improved predictive accuracy compared to the ICRG signature alone, as indicated by the areas under the receiver operating characteristic curves (AUC, nomogram:0.838; ICRGs:0.807). The study also evaluated the relationships between risk scores (RS) based on the expression of the ICRGs and other key immunotherapy variables, including immune checkpoint expression, immunophenoscore (IPS), and microsatellite instability (MSI). Integration of these variables led to more precise prediction of treatment efficacy, enabling personalized immunotherapy for COAD patients. Knocking down S1PR5 can enhance the efficacy of PD-1 monoclonal antibody, promoting the cytotoxicity of T cells against HCT116 cells ((p<0.05). Discussion: These findings indicate that the ICRG signature may be a valuable tool for predicting prognostic risk, evaluating the efficacy of immunotherapy, and tailoring personalized treatment options for patients with COAD.
immunology